Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) has received an average rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $3.70.

Several research firms have issued reports on MTNB. Piper Sandler began coverage on shares of Matinas BioPharma in a research note on Sunday, January 26th. They set an “overweight” rating and a $3.00 price target on the stock. Maxim Group reaffirmed a “buy” rating on shares of Matinas BioPharma in a research note on Wednesday. Zacks Investment Research cut shares of Matinas BioPharma from a “hold” rating to a “sell” rating in a research note on Wednesday, March 25th. Finally, SunTrust Banks started coverage on shares of Matinas BioPharma in a report on Thursday, January 23rd. They set a “buy” rating and a $3.00 price objective on the stock.

Matinas BioPharma stock opened at $0.76 on Wednesday. Matinas BioPharma has a 12-month low of $0.49 and a 12-month high of $2.49. The business’s 50-day moving average price is $0.68.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03).

Hedge funds have recently made changes to their positions in the company. Alpine Global Management LLC purchased a new position in Matinas BioPharma in the fourth quarter valued at approximately $138,000. Janney Montgomery Scott LLC purchased a new stake in shares of Matinas BioPharma during the fourth quarter valued at approximately $34,000. California Public Employees Retirement System purchased a new stake in shares of Matinas BioPharma during the fourth quarter valued at approximately $188,000. SG Americas Securities LLC purchased a new stake in shares of Matinas BioPharma during the fourth quarter valued at approximately $569,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Matinas BioPharma during the fourth quarter valued at approximately $454,000.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Further Reading: What does a bar chart mean for investors?

Analyst Recommendations for Matinas BioPharma (NYSEAMERICAN:MTNB)

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.